BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PR001 (LY3884961) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of PR001 (LY3884961)\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04411654-1699@assetmemo.bio
DTSTAMP:20261121T010148Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:PR001 (LY3884961): Phase 1/2 readout est. (NCT04411654)
DESCRIPTION:PR001 (LY3884961)\, phase 1/2.\nStudy: Phase 1/2 Clinical Trial
  of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)\nEstimated prim
 ary completion: February 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pr001-ly3884961#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04411654
URL:https://assetmemo.bio/drug/pr001-ly3884961#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05487599-1699@assetmemo.bio
DTSTAMP:20261121T010148Z
DTSTART;VALUE=DATE:20310830
DTEND;VALUE=DATE:20310831
SUMMARY:PR001 (LY3884961): Phase 1/2 readout est. (NCT05487599)
DESCRIPTION:PR001 (LY3884961)\, phase 1/2.\nStudy: A Clinical Trial of PR00
 1 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Diseas
 e (PROCEED)\nEstimated primary completion: 30 August 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pr001-ly3884961#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05487599
URL:https://assetmemo.bio/drug/pr001-ly3884961#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04127578-1699@assetmemo.bio
DTSTAMP:20261121T010148Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:PR001 (LY3884961): Phase 1/2 readout est. (NCT04127578)
DESCRIPTION:PR001 (LY3884961)\, phase 1/2\, Parkinson's Disease.\nStudy: Ph
 ase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's 
 Disease With at Least One GBA1 Mutation (PROPEL)\nEstimated primary comple
 tion: 31 August 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pr001-ly3884961#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04127578
URL:https://assetmemo.bio/drug/pr001-ly3884961#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
